POSFREA™

Permanent J-Code for Avyxa Pharma's POSFREA™ (palonosetron hydrochloride):


J2468


Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms

On July 1, 2024, Avyxa Pharma received a unique HCPCS for their palonosetron hydrochloride product; brand name: POSFREA™ (J2468). Avyxa's POSFREA™ was approved under the 505(b)(2) pathway and is therefore aligned to its own unique HCPCS. Avyxa's POSFREA™ (J2468) is not therapeutically equivalent to the generic palonosetron hydrochloride HCPCS (J2469).


Avyxa Pharma would appreciate your partnership in updating systems and locations involved with POSFREA's HCPCS and NDC information.


HCPCS Code Information:

HCPCS Code

J2468

HCPCS Code Descriptor

Injection, palonosetron hydrochloride (avyxa), not therapeutically equivalent to j2469, 25 micrograms

Manufacturer

Avyxa Pharma

NDC Codes

83831-0105-01

WAC Per HCPCS Unit

$58.00

NDC Code Information:

NDC Code

Package Description

WAC per Package

WAC per HCPCS Unit

83831-0105-01

POSFREA™- Palonosetron injection, solution 0.25mg/5mL (0.05mg/mL) SDV

$580.00

$58.00

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS AND IMPORTANT SAFETY INFORMATION FOR POSFREA™


INDICATIONS


Chemotherapy-Induced Nausea and Vomiting in Adults

POSFREA is indicated for:

  • Moderately emetogenic cancer chemotherapy -- prevention of acute and delayed nausea and vomiting associated with initial and repeat courses
  • Highly emetogenic cancer chemotherapy -- prevention of acute nausea and vomiting associated with initial and repeat courses


Postoperative Nausea and Vomiting in Adults

POSFREA is indicated for prevention of postoperative nausea and vomiting (PONV) for up to 24

hours following surgery. Efficacy beyond 24 hours has not been demonstrated.


As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is

little expectation that nausea and/or vomiting will occur postoperatively. In patients where

nausea and vomiting must be avoided during the postoperative period, POSFREA is

recommended even where the incidence of postoperative nausea and/or vomiting is low.


IMPORTANT SAFETY INFORMATION


CONTRAINDICATION

POSFREA is contraindicated in patients known to have hypersensitivity to the drug or any of its

components


WARNINGS AND PRECAUTIONS


Hypersensitivity

Hypersensitivity reactions, including anaphylaxis, have been reported with or without known

hypersensitivity to other 5-HT3 receptor antagonists.


Serotonin Syndrome

The development of serotonin syndrome has been reported with 5-HT3 receptor antagonists. Most

reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin

reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine

oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue).

Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of another 5-

HT3 receptor antagonist alone has also been reported. The majority of reports of serotonin

syndrome related to 5-HT3 receptor antagonist use occurred in a post-anesthesia care unit or an

infusion center.


Symptoms associated with serotonin syndrome may include the following combination of signs

and symptoms: mental status changes (e.g. agitation, hallucinations, delirium, and coma),

autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing,

hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia,

incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting,

diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with

concomitant use of POSFREA and other serotonergic drugs. If symptoms of serotonin syndrome

occur, discontinue POSFREA and initiate supportive treatment. Patients should be informed of the

increased risk of serotonin syndrome, especially if POSFREA is used concomitantly with other

serotonergic drugs.


ADVERSE REACTIONS


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates

observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials

of another drug and may not reflect the rates observed in practice.


The safety of POSFREA has been established from adequate and well-controlled studies of

another intravenous formulation of palonosetron HCl. Below is a display of the adverse reactions

of palonosetron HCl in these adequate and well-controlled studies.


Chemotherapy-Induced Nausea and Vomiting


In clinical trials for the prevention of nausea and vomiting induced by moderately or highly

emetogenic chemotherapy, 633 adult patients received a single 0.25 mg dose of palonosetron

HCl, 410 patients received a single 32 mg dose of ondansetron and 194 patients received a single

100 mg dose of dolasetron. Adverse reactions were similar in frequency and severity with

intravenous palonosetron HCl, ondansetron or dolasetron. The following adverse reactions were

reported by ≥ 2% of patients in these trials who received palonosetron HCL 0.25 mg

intravenously, ondansetron 32 mg intravenously, or dolasetron 100 mg intravenously,

respectively: headache (9%, 8%, 16%, respectively), constipation (5%, 2%, 6%, respectively),

diarrhea (1%, 2%, 2%, respectively), dizziness (1%, 2%, 2%, respectively), fatigue (<1%, 1%,

2%, respectively), abdominal pain (<1%, <1%, 2%, respectively), insomnia (<1%, 1%, 2%,

respectively).


In other studies, 2 subjects experienced severe constipation following a single palonosetron HCl

dose of approximately 0.75 mg, three times the recommended dose.


In clinical trials, the following infrequently reported adverse reactions, assessed by investigators

as treatment-related or causality unknown, occurred following administration of palonosetron

HCl to adult patients receiving concomitant cancer chemotherapy:


Cardiovascular: 1%: non-sustained tachycardia, bradycardia, hypotension, < 1%: hypertension,

myocardial ischemia, extrasystoles, sinus tachycardia, sinus arrhythmia, supraventricular

extrasystoles and QT prolongation. In many cases, the relationship to palonosetron was unclear.


Dermatological: < 1%: allergic dermatitis, rash.


Hearing and Vision: < 1%: motion sickness, tinnitus, eye irritation and amblyopia.


Gastrointestinal System: 1%: diarrhea, < 1%: dyspepsia, abdominal pain, dry mouth, hiccups and

flatulence.


General: 1%: weakness, < 1%: fatigue, fever, hot flash, flu-like syndrome.


Liver: < 1%: transient, asymptomatic increases in AST and/or ALT and bilirubin. These changes

occurred predominantly in patients receiving highly emetogenic chemotherapy.


Metabolic: 1%: hyperkalemia, < 1%: electrolyte fluctuations, hyperglycemia, metabolic acidosis,

glycosuria, appetite decrease, anorexia.


Musculoskeletal: < 1%: arthralgia.


Nervous System: 1%: dizziness, < 1%: somnolence, insomnia, hypersomnia, paresthesia.


Psychiatric: 1%: anxiety, < 1%: euphoric mood.


Urinary System: < 1%: urinary retention.


Vascular: < 1%: vein discoloration, vein distention.


Postoperative Nausea and Vomiting

Adverse reactions occurred in adults receiving intravenous palonosetron HCl 0.075 mg

immediately before induction of anesthesia in three randomized placebo-controlled trials. Rates

of adverse reactions between palonosetron HCl and placebo groups were similar. Some events

are known to be associated with, or may be exacerbated by concomitant perioperative and

intraoperative medications administered in this surgical population. The following adverse

reactions were reported by ≥ 2% of patients in these trials who received palonosetron HCL 0.075

mg intravenously compared to placebo: electrocardiogram QT prolongation (5% vs. 3%),

bradycardia (4% vs. 4%), headache (3% vs 4%), and constipation (2% vs 3%).


In these clinical trials, the following infrequently reported adverse reactions, assessed by

investigators as treatment-related or causality unknown, occurred following administration of

palonosetron HCl to adult patients receiving concomitant perioperative and intraoperative

medications including those associated with anesthesia:


Cardiovascular: 1% electrocardiogram QTc prolongation, sinus bradycardia, tachycardia; <1%:

blood pressure decreased, hypotension, hypertension, arrhythmia, ventricular extrasystoles,

generalized edema; ECG T wave amplitude decreased, platelet count decreased. The frequency

of these adverse effects did not appear to be different from placebo.


Dermatological: 1%: pruritus.


Gastrointestinal System: 1%: flatulence, < 1%: dry mouth, upper abdominal pain, salivary

hypersecretion, dyspepsia, diarrhea, intestinal hypomotility, anorexia.


General: < 1%: chills.


Liver: 1%: increases in AST and/or ALT< 1%: hepatic enzyme increased


Metabolic: < 1%: hypokalemia, anorexia.


Nervous System: < 1%: dizziness.


Respiratory: < 1%: hypoventilation, laryngospasm.


Urinary System: 1%: urinary retention.


Postmarketing Experience

The following adverse reactions have been identified during post approval use of another

intravenous formulation of palonosetron HCl. Because these reactions are reported voluntarily

from a population of uncertain size, it is not always possible to reliably estimate their frequency

or establish a causal relationship to drug exposure.


Very rare cases (<1/10,000) of hypersensitivity reactions including anaphylaxis and anaphylactic

shock and injection site reactions (burning, induration, discomfort and pain) were reported from

postmarketing experience of palonosetron HCl 0.25 mg in the prevention of chemotherapyinduced

nausea and vomiting.


DRUG INTERACTIONS


Serotonergic Drugs

Serotonin syndrome (including altered mental status, autonomic instability, and neuromuscular

symptoms) has been described following the concomitant use of 5-HT3 receptor antagonists and

other serotonergic drugs, including selective serotonin reuptake inhibitors (SSRIs) and serotonin

and noradrenaline reuptake inhibitors (SNRIs). Monitor for the emergence of serotonin syndrome.

If symptoms occur, discontinue POSFREA and initiate supportive treatment.


USE IN SPECIFIC POPULATIONS


Pregnancy


Risk Summary

There are no available data on palonosetron HCl use in pregnant women to inform a drugassociated

risk. In animal reproduction studies, no effects on embryo-fetal development were

observed with the administration of oral palonosetron HCl to rats and rabbits during

organogenesis at doses up to 1894 and 3789 times the recommended human intravenous dose,

respectively [see Data below].


The estimated background risk of major birth defects and miscarriage for the indicated

population is unknown. In the U.S. general population, the estimated background risk of major

birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%,

respectively.


Data


Animal Data

In animal reproduction studies, no effects on embryo-fetal development were observed in

pregnant rats given oral palonosetron HCl at doses up to 60 mg/kg/day (1894 times the

recommended human intravenous dose based on body surface area) or pregnant rabbits given

oral doses up to 60 mg/kg/day (3789 times the recommended human intravenous dose based on

body surface area) during the period of organogenesis.


Lactation


Risk Summary

There are no data on the presence of palonosetron in human milk, the effects of palonosetron on

the breastfed infant, or the effects of palonosetron on milk production. The developmental and

health benefits of breastfeeding should be considered along with the mother's clinical need for

POSFREA and any potential adverse effects on the breastfed infant from palonosetron or from

the underlying maternal condition.


Pediatric Use

This product has not been approved for use in pediatric patients for prevention of chemotherapyinduced

nausea and vomiting.


The safety and effectiveness of POSFREA for prevention of postoperative nausea and vomiting

have not been established in pediatric patients.


Geriatric Use

Of the 1374 adult cancer patients in clinical studies of intravenously administered palonosetron

HCl for CINV, 316 (23%) were aged 65 years and over, while 71 (5%) were aged 75 years and

over. Of the 1520 adult patients in clinical studies of intravenously administered palonosetron

HCl for PONV, 73 (5%) were age 65 years older. No overall differences in safety or

effectiveness were observed between these subjects and the younger subjects, but greater

sensitivity in some older individuals cannot be ruled out. Population pharmacokinetics analysis

did not reveal any differences in palonosetron pharmacokinetics between cancer patients ≥ 65

years of age and younger patients. No dose adjustment or special monitoring are required for

geriatric patients.


No overall differences in safety were observed between older and younger subjects in these

studies, though the possibility of heightened sensitivity in some older individuals cannot be

excluded. No differences in efficacy were observed in geriatric patients for the CINV indication

and none are expected for geriatric PONV patients. However, palonosetron HCl efficacy in

geriatric patients has not been adequately evaluated.


OVERDOSAGE

There is no known antidote to palonosetron HCl. Overdose should be managed with supportive

care.


Dialysis studies have not been performed, however, due to the large volume of distribution,

dialysis is unlikely to be an effective treatment for palonosetron HCl overdose. A single

intravenous dose of palonosetron HCl at 30 mg/kg (947 and 474 times the human dose for rats

and mice, respectively, based on body surface area) was lethal to rats and mice. The major signs

of toxicity were convulsions, gasping, pallor, cyanosis and collapse.

Please see the full Prescribing information for safety information, including BOXED WARNING, and dosing guidelines.


To report SUSPECTED ADVERSE REACTIONS, contact Avyxa Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

© Copyrights 2024 Avyxa | All Rights Reserved

03/2024